Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Thursday

Viridian Therapeutics (NASDAQ:VRDN) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Viridian Therapeutics Trading Up 2.3%

VRDN stock opened at $28.07 on Tuesday. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $34.29. The company has a market capitalization of $2.68 billion, a PE ratio of -9.29 and a beta of 0.98. The company’s 50-day simple moving average is $31.26 and its 200 day simple moving average is $26.18. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.28 and a current ratio of 11.28.

Analyst Upgrades and Downgrades

VRDN has been the topic of a number of analyst reports. Royal Bank Of Canada increased their target price on shares of Viridian Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Truist Financial reduced their price target on Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. UBS Group initiated coverage on Viridian Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, January 21st. Finally, Evercore restated an “outperform” rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 20th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.64.

Insiders Place Their Bets

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 2,272 shares of the business’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total transaction of $70,795.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.65% of the stock is owned by company insiders.

Institutional Investors Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in VRDN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Viridian Therapeutics by 1.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after purchasing an additional 876 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Viridian Therapeutics by 33.8% during the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after buying an additional 310,998 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Viridian Therapeutics by 12.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock valued at $1,760,000 after acquiring an additional 14,788 shares during the last quarter. Envestnet Asset Management Inc. acquired a new stake in shares of Viridian Therapeutics during the 2nd quarter valued at $187,000. Finally, Creative Planning acquired a new stake in shares of Viridian Therapeutics during the 2nd quarter valued at $179,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.